Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Pinto-Plata | Peter M.A. Chang Electronic publication date: 30/06/2016 Collection year: 2016 Pulmonary & Respiratory Medicine Journal is one of the best open access journals that aims to publish the most complete and reliable source of information on discoveries and current developments in the mode of original articles, review articles, case reports, short communications, etc. in the field and provide on-line access to the researchers worldwide without any restrictions or subscriptions. If you wish to make any changes to supplementary data during any stage of the process, then please make sure to provide an updated file, and do not annotate any corrections on a previous version. Eschenbacher | Jeffrey A. The final decision-making responsibility lies with the handling editor, who reserves the right to reject the paper despite favourable reviews depending on the priorities of the journal. Respiratory Medicine is an internationally-renowned, clinically-oriented journal, combining cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions, but with a clear clinical relevance. list of medical interview questionsKennedy | James Bergen | Jose A. Kristin Larsen | Guy E.J.
Carley and his colleagues at boththe University of Illinois at Chicago and Northwestern University for the successful completion of the PACE trial.These positive results clearly demonstrate the potential for dronabinol to treat OSA, a serious condition affecting millions of people with very few viable treatment options.We plan to move forward with the development of dronabinol in OSA, and plan to meet with the FDA for a Special Protocol Assessment (“SPA”) to finalize the Phase 3 study required for approval using both fast track and breakthrough designations from the FDA to facilitate the development path.” interview skills workshopJames S. Manuso, Ph.D., President, Chief Executive Officer and Vice Chairman stated, “We are very excited with the possibility of bringing to market the first drug treatment for OSA. We can now envision a small molecule, easy to use, oral medicine for OSA patients as an alternative to CPAP (continuous positive airway pressure) devices, surgery and other methods used to treat this underappreciated disease, which has such enourmous costs to society.” “We look forward to discussing with investors the results of this trial at upcoming conferences.” Background Obstructive Sleep Apnea is the most common form of sleep apnea and affects 29.4 million Americans according to Frost & Sullivan. 5.9 million adults are diagnosed (23.5 million are undiagnosed).OSA, besides causing next day sleepiness which is a major cause of motor vehicle and industrial accidents, is also co-morbid with cardiovascular disease, type 2 diabetes and other conditions.Treatment options are limited and the most effective treatment, the CPAP device has an extremely high non-compliance rate. The overall cost to the U.S. economy of the diagnosed and undiagnosed portions of the OSA market are estimated to be $12.4 billion and $149.6 billion respectively for a total cost of $162.0 billion in 2015. There is no drug therapy approved for OSA.While certain stimulants such as modafinil and methylphenidate are FDA approved for next day sleepiness in certain OSA patients, they do not treat OSA itself.Dronabinol, currently formulated as a capsule, is believed to be much more user friendly than the current devices, should have a higher patient compliance rate, should work well in the moderate to mild patient segment, which represents approximately 50% of the overall OSA patient population, and may result in more of the currently undiagnosed patient population getting diagnosed. Read More Dronabinol is synthetic 9-THC (delta 9-tetrahydrocannabinol), one of the active cannabinoids found in marijuana.It is approved in the United States in 2.5mg, 5mg and 10mg capsules for the treatment of anorexia associated with AIDS and chemo-therapy induced nausea and vomiting.It is a schedule III drug meaning there is a low abuse potential, but it is monitored by the United States DEA (drug enforcement agency). It is Medicare part B reimbursed for its current approved indications.
For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/respirerx-pharmaceuticals-inc-announces-positive-130000109.html
You may also be interested to read
- medical interview bmj
- browse around this website
- check that
- this contact form